243 related articles for article (PubMed ID: 9231923)
1. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
2. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
[TBL] [Abstract][Full Text] [Related]
4. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
Vaidyanathan G; Strickland DK; Zalutsky MR
Int J Cancer; 1994 Jun; 57(6):908-13. PubMed ID: 8206683
[TBL] [Abstract][Full Text] [Related]
5. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
Vaidyanathan G; Zalutsky MR
Bioconjug Chem; 1992; 3(6):499-503. PubMed ID: 1463779
[TBL] [Abstract][Full Text] [Related]
6. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
8. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
10. (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Med Chem; 1994 Oct; 37(21):3655-62. PubMed ID: 7932592
[TBL] [Abstract][Full Text] [Related]
11. No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1996; 7(1):102-7. PubMed ID: 8741997
[TBL] [Abstract][Full Text] [Related]
12. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
15. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
Cunningham SH; Mairs RJ; Wheldon TE; Welsh PC; Vaidyanathan G; Zalutsky MR
Br J Cancer; 1998 Jun; 77(12):2061-8. PubMed ID: 9649115
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
18. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
Vaidyanathan G; Affleck DJ; Alston KL; Welsh P; Zalutsky MR
Nucl Med Commun; 2004 Sep; 25(9):947-55. PubMed ID: 15319601
[TBL] [Abstract][Full Text] [Related]
19. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
20. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
Armour A; Mairs RJ; Gaze MN; Wheldon TE
Br J Cancer; 1994 Sep; 70(3):445-8. PubMed ID: 8080728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
